Fresenius Medical Care (NYSE:FMS) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Fresenius Medical Care (NYSE:FMS) in a report published on Friday. The firm issued a strong-buy rating on the stock.

A number of other equities analysts have also commented on FMS. Truist Financial increased their price target on Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Finally, Berenberg Bank started coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price target on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Fresenius Medical Care has a consensus rating of “Hold” and a consensus price target of $24.30.

Fresenius Medical Care Stock Up 1.0 %

FMS opened at $22.38 on Friday. The company has a market capitalization of $13.13 billion, a PE ratio of 18.50, a price-to-earnings-growth ratio of 0.96 and a beta of 0.92. The firm has a 50-day simple moving average of $22.24 and a two-hundred day simple moving average of $20.66. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. Fresenius Medical Care has a 52 week low of $17.93 and a 52 week high of $24.31.

Institutional Investors Weigh In On Fresenius Medical Care

Several institutional investors have recently modified their holdings of FMS. Allworth Financial LP raised its holdings in Fresenius Medical Care by 53.1% during the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock valued at $36,000 after buying an additional 581 shares during the period. Mercer Global Advisors Inc. ADV raised its stake in shares of Fresenius Medical Care by 4.5% in the second quarter. Mercer Global Advisors Inc. ADV now owns 14,581 shares of the company’s stock valued at $278,000 after acquiring an additional 624 shares during the period. MML Investors Services LLC lifted its holdings in shares of Fresenius Medical Care by 5.3% in the 3rd quarter. MML Investors Services LLC now owns 15,019 shares of the company’s stock worth $320,000 after acquiring an additional 753 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Fresenius Medical Care by 6.7% during the 2nd quarter. Rhumbline Advisers now owns 18,067 shares of the company’s stock worth $345,000 after purchasing an additional 1,128 shares during the period. Finally, Marshall Wace LLP grew its holdings in Fresenius Medical Care by 8.5% during the 2nd quarter. Marshall Wace LLP now owns 15,363 shares of the company’s stock valued at $293,000 after purchasing an additional 1,207 shares during the last quarter. 8.37% of the stock is owned by institutional investors.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.